Best Selank source is not a claim worth making before the scoring is on the table, so the weighting comes first and the ranking second. Six supplier categories, judged on what a buyer can verify from outside the business, rather than on which storefront looks most convincing at the end of a heavy week.
Key takeaways
- Testing scope carries the heaviest weight, because FDA's documented concern with Selank is immunogenicity from aggregation and peptide-related impurities, which is a laboratory question rather than a reputational one.
- The compounding pharmacy row scores near zero on availability rather than on quality. The bulk nomination was withdrawn, so there is no ordinary route through one.
- The most consumer-friendly category, the nootropic retailer selling a nasal spray, scores worst on everything a buyer can actually check, starting with a stated milligram quantity.
- The winning category wins on paperwork, not on results. It is a domestic research supplier publishing batch-specific reports from a named laboratory.
- Even our top-scoring listing loses marks in this table, because its testing scope moves between batches and the certificate the product page links is the thinner of the two.
The listing that sits in the top category is below, put up front rather than saved as a conclusion, so the scoring can be argued with while the numbers are visible.
The vendor we point lifters to
Selank from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
The published certificate for lot 29-01260229 assays this vial at 12.29 mg against a 10 mg label, and reports no endotoxin or sterility testing. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 21, 2026.
The weighting, published before anything is ranked
| Criterion | Weight | What earns full marks |
|---|---|---|
| Testing scope | 30 | Identity by mass spectrometry, numeric purity with the chromatogram, and a bacterial endotoxins result, published rather than promised |
| Batch traceability | 20 | A lot number on the report that matches the vial, a test date, and a named third-party laboratory |
| Availability | 15 | Can lawfully and reliably ship the material at all, to an ordinary buyer |
| Dispatch and recourse | 15 | Domestic dispatch with tracking, a named business, a stated returns position |
| Price transparency | 12 | A published figure that converts to a per-milligram number in one step |
| Format clarity | 8 | The form and a milligram quantity stated plainly, so the product can be compared to anything |
Testing scope takes almost a third on its own, and the reason is documented rather than editorial. Availability gets its own column here, which it does not need on most compounds, because on Selank one whole category fails on that criterion alone regardless of how good it would otherwise be.
Best Selank source: six categories against that weighting
| Category | Testing /30 | Traceability /20 | Availability /15 | Dispatch /15 | Price /12 | Format /8 | Total |
|---|---|---|---|---|---|---|---|
| Domestic research supplier, named-lab batch reports | 20 | 18 | 15 | 13 | 12 | 8 | 86 |
| Domestic research supplier, catalog certificate only | 9 | 6 | 15 | 12 | 10 | 7 | 59 |
| Life-science reagent catalog | 24 | 18 | 4 | 5 | 3 | 6 | 60 |
| Nootropic retailer, nasal spray | 4 | 3 | 13 | 10 | 4 | 2 | 36 |
| Overseas bulk seller | 5 | 4 | 8 | 3 | 11 | 5 | 36 |
| Compounding pharmacy | 14 | 12 | 1 | 8 | 2 | 6 | 43 |
| Grey-market reseller or group buy | 1 | 0 | 6 | 2 | 8 | 3 | 20 |
Three results in that table are worth arguing with, and all three are argued with below: the category with the best documentation cannot practically be bought from, the category that looks most legitimate cannot supply the product at all, and the friendliest shopping experience scores level with the worst one.
Why testing scope carries almost a third
FDA's stated concern with Selank appears on its page on bulk substances that may present significant safety risks, content current as of 04/22/2026:
"Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."
Read that as a specification rather than a warning label. Aggregation and peptide-related impurities are outcomes of how material is synthesised, handled and stored, which is what identity and purity testing interrogate. Endotoxin is a separate question again: it is bacterial debris rather than living organisms, it persists after the bacteria that produced it are gone, and it is measured by its own compendial assay. A spotless chromatogram says nothing about it, because a chromatogram is not the instrument that finds it. A supplier whose linked certificate publishes purity alone has therefore answered the easiest of the three questions, and on this vendor that scope holds on one batch and not on the next, which is why the top row scores 20 out of 30 rather than 30.
The availability column, and the row most readers expect to win
Compounding pharmacies score 43 and land mid-table, entirely because of one column.
Selank holds no FDA approval for any indication. It was nominated as a bulk drug substance for use in compounding, was placed in category 2 under FDA's interim policies while the agency evaluated it, and the nomination was then withdrawn by the nominator. It appears on that same FDA safety risks page under the heading "Bulk drug substances nominated but withdrawn", named as "Selank acetate (TP-7)", and it is absent from FDA's 503A bulk substances page in every category.
That is the precise position, and it is worth getting right because most competing pages do not. Nominated, evaluated, withdrawn, currently on no list. Not "FDA Category 2", a status it no longer holds, and not "banned from compounding", which it never was.
A pharmacy scores well on the columns it would touch, which is why its testing and traceability numbers are not low. It scores 1 on availability because in practice it cannot supply the material, and one advertising Selank anyway is not a find but a question about where its bulk substance came from. The same withdrawn-nomination shape on a compound lifters ask about more often is in our BPC-157 supplier scoring.
Selank does carry a Russian anxiolytic registration. That is a foreign registration: not FDA approval, not something a US pharmacy dispenses against, and not evidence of efficacy by Western regulatory standards.
The category with the best paperwork and the worst practicality
Life-science reagent catalogs score highest of any category on testing and traceability, at 24 and 18, and finish sixtieth-percentile overall.
The documentation is genuinely better because the customers are institutions that get audited. What breaks is everything else: quantities are small, unit prices are far above the research market, purchasing usually requires an institutional account and a business shipping address, and lead times are built for a procurement department rather than a person. A scoring table that ignored practicality would rank it first and mislead every reader, which is why availability and dispatch are columns rather than footnotes.
The friendliest storefront, scored honestly
The nootropic retailer selling a Selank nasal spray scores 36, level with an overseas bulk seller, and readers usually find that harsh until they look at the format column.
A research supplier sells lyophilised powder in a sealed vial with a milligram figure on the label. A spray listing frequently states content per spray, or per bottle, or not in milligrams at all. Without a milligram figure, the product cannot be priced per unit, compared against another spray, or checked against a certificate even in principle. That is a 2 out of 8, and it drags the price column down with it. Format also shifts the sterility burden onto preservation and manufacturing control in a way a sealed powder does not, and most of these listings publish no certificate to inspect.
The top row, and where it loses marks
Ascension's Selank 10 mg sits in the winning category. It lists at $47.50 against a $60.00 reference price, drops to $23.75 with PEPTIDEDECK for $2.38 per milligram, dispatches same day before 2pm CST, offers free shipping above $250, and carries research-use language while declining to discuss reconstitution or amounts.
The product is a defined object with public reference values behind it. Selank is a synthetic heptapeptide, seven residues, Thr-Lys-Pro-Arg-Pro-Gly-Pro, an analogue of the immune peptide tuftsin with a Pro-Gly-Pro tail added to slow enzymatic breakdown. PubChem CID 11765600 gives C33H57N11O9 and a molecular weight of 751.9.
The certificate the product page links is from MZ Biolabs in Tucson for lot 29-01260229, analysis date 2026-02-07. It reports purity at 99.32% by HPLC-UV with the chromatogram and peak list shown, confirms identity by mass spectrometry with an expected monoisotopic mass of 751.43 Da against 751.47 Da measured, and reports a measured quantity of 12.29 mg per vial against a 10 mg label. Publishing an assayed quantity that can be measured against you is unusual and deserves credit, and it is lot-specific rather than a guarantee about a future vial.
Here is where the ten marks went. Searching that document for endotoxin, LAL, pyrogen or sterility returns nothing, because none of those tests are on it. The later batch is a different document. The Kovera Labs report for 29-05260628, certified 06/02/2026, adds a bacterial endotoxin result below 0.20 EU/mL against a 0.5 EU/mL limit, a rapid two-day sterility screen returning no growth, and heavy metals by ICP-MS. So the category does answer the question FDA's language raises, on some batches, which is why it scores well rather than fully. Testing scope here is a property of the batch rather than of the vendor, and the fuller document is not the one the page links, so read every certificate on the product page and ask which lot you will actually be shipped.
The same method, applied where the documented failure mode is different, is in how we weight an NAD+ supplier, where provenance rather than endotoxin does most of the work.
What first place cannot buy
A top-scoring supplier buys confidence about the contents of a container. It does not buy an outcome, and that distinction matters more here than the price does. There is no finished Western efficacy trial establishing what Selank does in healthy trained people, Russian-language work is routinely cited second hand at a strength the original does not support, and the registered trial record is the check on any supplier implying otherwise.
For a lifter in the month that prompted the search, the causes with real evidence behind them cost nothing and deserve the first pass: sleep debt, an aggressive deficit, and accumulated volume with no deload in sight. We cover the first in sleep, cortisol and myostatin, a duller read than a ranking table for the same reason it is a better one.
Frequently asked questions
What makes one Selank source better than another?
Testing scope, weighted at nearly a third here, followed by batch traceability. A source publishing identity by mass spectrometry against the expected 751.43 Da, a numeric purity result with the chromatogram behind it, and a bacterial endotoxins figure is answering the question FDA actually raised. Everything else is secondary.
Why does a compounding pharmacy score so poorly?
Not on quality, on availability. Selank's bulk nomination was withdrawn and it appears on no current 503A category list, so there is no ordinary route through a pharmacy. A pharmacy advertising it is an outlier worth asking hard questions of rather than a better option.
Should I buy from a life-science reagent catalog instead?
Their documentation is the best in the table, and the format is built for institutions: small quantities, high unit prices, account verification and business shipping addresses. It is a legitimate channel working exactly as intended for its own audience rather than a practical route for an individual.
Why does the top-ranked listing not score full marks?
Because testing scope here moves between batches. The certificate the product page links, for lot 29-01260229, covers identity, purity and quantity and does not cover endotoxin, sterility or pyrogens; the later batch 29-05260628 adds all three. It is the strongest category available in this channel, and which lot is being shipped is still the question to put to the seller.
Does a better source make Selank work?
No, and no source can promise that. There is no finished Western efficacy trial in healthy trained people, and a Russian anxiolytic registration is a foreign registration rather than an approval or evidence by Western standards. The supplier decision is about what is in the container and nothing beyond it.
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA
- Bulk Drug Substances Used in Compounding Under Section 503A, FDA
- Selank, PubChem CID 11765600
- Certificate of analysis, Selank lot 29-01260229, MZ Biolabs
- Certificate of analysis, Selank batch 29-05260628, Kovera Labs
- Registered studies of Selank, ClinicalTrials.gov
This article is for educational purposes only and is not medical advice. Selank holds no FDA approval for any indication, material sold by research suppliers is labeled for laboratory use only and not for human consumption, and a foreign registration is not an FDA approval or evidence of efficacy by Western regulatory standards. Speak with a qualified healthcare professional before making any decision involving peptides, injections or off-label compounds.